Abstract:Abstract Background The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation. Methods Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays. Results In silico modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called 76 . From this screen, several compounds, termed 76.2 , 76.3 , and 76.4 sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound 76 . Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins. Conclusion These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.

ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Targeting the ERK signaling pathway in cancer therapy

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

A Death-Promoting Role For Extracellular Signal-Regulated Kinase

Progress in the development of ERK1/2 inhibitors for treating cancer and other diseases

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Dual Effects of Active ERK in Cancer: A Potential Target for Enhancing Radiosensitivity (Review)

Targeting RAS–ERK signalling in cancer: promises and challenges

ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

The Overview of Mitogen-activated Extracellular Signal-Regulated Kinase (Mek)-Based Dual Inhibitor in the Treatment of Cancers.

AKT and ERK dual inhibitors: The way forward?

Targeting ERK-MYD88 interaction leads to ERK dysregulation and immunogenic cancer cell death

ERK1/2 MAP Kinases in Cell Survival and Apoptosis